OncoBeta® GmbH located at the Garching Technology and Start-up Centre, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today that Prof. Mike Sathekge from the University of Pretoria, Steve Biko Academic Hospital Nuclear Medical department and his clinical team has treated the first non-melanocytic skin cancer patients in South Africa with the innovative Rhenium-SCT® skin cancer treatment System. This next-generation radionuclide therapy technology applied by the nuclear medicine physician offers a new singles session, painless treatment for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs). The global incidence of non-melanoma skin cancers has drastically increased over the few past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas with South Africa having one of the highest incidence rates in the world.

Prof. Mike Sathekge and his team at the University of Pretoria, Steve Biko Academic Hospital are focused on providing patients with personalized care using state-of-the-art technology that can deliver high-precision therapy and diagnostics with minimal side effects. The specialized team of experts in the nuclear medicine and medical physics, work closely with other disciplines within the university hospital, referring physicians, and other institutions, to ensure patients receive the best possible treatment for their specific type of cancer.

Martin Magwaza, CEO of Tautomer (PTY) LTD Oncobeta®’s distribution partner for the Rhenium-SCT® in Africa, is dedicated to providing South Africans with new innovative and effective therapies across the continent, coordinating with representatives from all levels of government and state for the health care landscape.

“The start of the Rhenium-SCT® in South Africa is a significant milestone in the international expansion of our ground-breaking treatment for BCCs and SCCs.," said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "Our vision of bringing a revolutionary affordable skin cancer therapy to physicians and patients all over the world has come one step closer today”.

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat.  The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.

Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/…

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Über die gate Garchinger Technologie- und Gründerzentrum GmbH

The business incubator offers optimum conditions for a successful business start.
Founders at gate profit not only from the proximity to research and development institutions on campus but also from the additional business services. The startups can use conference rooms in different sizes which fit their requirements. An experienced business coach advises the young teams at no extra charge. Networking events and workshops take place regularly to connect the community and encourage the entrepreneurs. The in-house reception including a postal service is also part of the benefits.
If you have a tech-startup, e.g. in the sector of automotive, big data, industry 4.0, internet of the things, health care, robotics, or smart mobility feel free to contact us and find out more about ʺthe gate“.
www.gategarching.com

Firmenkontakt und Herausgeber der Meldung:

gate Garchinger Technologie- und Gründerzentrum GmbH
Lichtenbergstraße 8
85748 Garching bei München
Telefon: +49 (89) 5484-0
Telefax: +49 (89) 5484-1010
http://www.gategarching.com

Ansprechpartner:
Lisa Hyna
Marketing & Öffentlichkeitsarbeit
Telefon: +49 (89) 54841110
Fax: +49 (89) 54841010
E-Mail: lisa.hyna@gategarching.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.